Stockscreener 앱 받기
703.39
2.60%
18.96
전일 마감가:
$684.43
열려 있는:
$694.2
하루 거래량:
5.56M
Relative Volume:
1.29
시가총액:
$665.09B
수익:
$53.26B
순이익/손실:
$13.80B
주가수익비율:
45.97
EPS:
15.3
순현금흐름:
$-50.20M
1주 성능:
+12.24%
1개월 성능:
-9.01%
6개월 성능:
-16.82%
1년 성능:
-24.62%
1일 변동 폭
$685.80
$705.78
1주일 범위
$625.90
$705.78
52주 변동 폭
$623.78
$972.53
일라이 릴리 Stock (LLY) Company Profile
명칭
Lilly Eli Co
전화
(317) 276-2000
주소
LILLY CORPORATE CTR, INDIANAPOLIS, IN
LLY을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
LLY
Lilly Eli Co
|
702.72 | 592.10B | 53.26B | 13.80B | -50.20M | 15.30 |
|
JNJ
Johnson Johnson
|
176.81 | 420.06B | 90.62B | 22.66B | 18.18B | 9.35 |
|
ABBV
Abbvie Inc
|
206.66 | 355.91B | 58.33B | 3.73B | 18.24B | 2.10 |
|
NVS
Novartis Ag Adr
|
124.05 | 234.63B | 53.40B | 13.68B | 16.89B | 6.9231 |
|
MRK
Merck Co Inc
|
84.58 | 206.59B | 63.43B | 16.42B | 14.72B | 6.49 |
일라이 릴리 Stock (LLY) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-08-07 | 다운그레이드 | Leerink Partners | Outperform → Market Perform |
| 2025-06-05 | 다운그레이드 | Erste Group | Buy → Hold |
| 2025-04-28 | 다운그레이드 | HSBC Securities | Buy → Reduce |
| 2025-04-22 | 개시 | Cantor Fitzgerald | Overweight |
| 2024-12-10 | 재개 | BofA Securities | Buy |
| 2024-11-15 | 개시 | Wolfe Research | Outperform |
| 2024-10-17 | 개시 | Bernstein | Outperform |
| 2024-09-13 | 재개 | Citigroup | Buy |
| 2024-08-12 | 업그레이드 | Deutsche Bank | Hold → Buy |
| 2024-02-21 | 다운그레이드 | DZ Bank | Buy → Hold |
| 2024-02-16 | 재확인 | Morgan Stanley | Overweight |
| 2023-12-21 | 다운그레이드 | Daiwa Securities | Buy → Outperform |
| 2023-11-09 | 개시 | Deutsche Bank | Hold |
| 2023-10-20 | 재개 | UBS | Buy |
| 2023-08-09 | 업그레이드 | Jefferies | Hold → Buy |
| 2023-07-26 | 재확인 | Citigroup | Buy |
| 2023-07-14 | 개시 | HSBC Securities | Buy |
| 2023-05-24 | 재확인 | BofA Securities | Buy |
| 2023-05-24 | 재확인 | UBS | Buy |
| 2023-03-13 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
| 2023-03-06 | 개시 | Jefferies | Hold |
| 2023-02-15 | 다운그레이드 | Societe Generale | Hold → Sell |
| 2022-11-18 | 개시 | Credit Suisse | Outperform |
| 2022-09-22 | 업그레이드 | UBS | Neutral → Buy |
| 2022-05-23 | 개시 | SVB Leerink | Outperform |
| 2022-04-06 | 재개 | Morgan Stanley | Overweight |
| 2022-03-10 | 개시 | Daiwa Securities | Outperform |
| 2022-01-21 | 업그레이드 | DZ Bank | Hold → Buy |
| 2022-01-03 | 재확인 | Bernstein | Mkt Perform |
| 2021-12-17 | 개시 | Goldman | Neutral |
| 2021-12-16 | 재확인 | BMO Capital Markets | Outperform |
| 2021-12-16 | 재확인 | BofA Securities | Buy |
| 2021-12-09 | 재개 | Wells Fargo | Equal Weight |
| 2021-11-19 | 개시 | BMO Capital Markets | Outperform |
| 2021-10-11 | 업그레이드 | Berenberg | Hold → Buy |
| 2021-09-29 | 업그레이드 | Citigroup | Neutral → Buy |
| 2021-08-05 | 업그레이드 | DZ Bank | Hold → Buy |
| 2021-07-27 | 재개 | Truist | Buy |
| 2021-06-24 | 재확인 | Cantor Fitzgerald | Overweight |
| 2021-01-19 | 업그레이드 | Mizuho | Neutral → Buy |
| 2020-12-10 | 업그레이드 | Wolfe Research | Peer Perform → Outperform |
| 2020-11-10 | 재개 | Bernstein | Mkt Perform |
| 2020-09-29 | 개시 | Berenberg | Hold |
| 2020-09-03 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2020-06-16 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2020-04-21 | 다운그레이드 | UBS | Buy → Neutral |
| 2020-04-09 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2020-02-06 | 개시 | Mizuho | Neutral |
| 2019-12-18 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2019-10-17 | 재개 | BofA/Merrill | Buy |
| 2019-05-28 | 개시 | Goldman | Buy |
| 2019-04-24 | 업그레이드 | Edward Jones | Hold → Buy |
| 2019-04-11 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2019-03-12 | 개시 | JP Morgan | Overweight |
| 2019-01-23 | 개시 | UBS | Buy |
| 2018-11-26 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2018-10-31 | 업그레이드 | Credit Suisse | Underperform → Neutral |
| 2018-10-09 | 개시 | Guggenheim | Buy |
| 2018-10-01 | 재확인 | SunTrust | Buy |
| 2018-09-26 | 재개 | JP Morgan | Overweight |
모두보기
일라이 릴리 주식(LLY)의 최신 뉴스
Texas Lawsuit Filed Against Eli Lilly (LLY) Amid New Cardio Collaboration - simplywall.st
Eli Lilly and Co: Steve Mandel's Strategic Exit with a -3.94% Portfolio Impact - uk.finance.yahoo.com
Lilly signs $1.3 billion deal with Superluminal to discover obesity medicines using AI - Reuters
UK patients rush for obesity jab before Eli Lilly raises price 170% to appease Donald Trump - Financial Times
Eli Lilly hikes Mounjaro prices in the UK to make weight-loss drug cheaper in the US - CNN
Eli Lilly raises UK price of Mounjaro, a look at salary of CEO David A. Ricks - NationalWorld
Eli Lilly takes slim bet with bloated UK pricing - Breakingviews
Eli Lilly to hike UK price of weight-loss drug Mounjaro - Proactive financial news
Eli Lilly Strikes $1.3 Billion Deal With Superluminal To Develop AI-Driven Obesity Drugs - inkl
Jim Cramer Says He is “Very Upset” With Eli Lilly - Insider Monkey
Mounjaro weight-loss drug price to almost triple in UK after Trump complaint - The Independent
Director Makes a Bold Move with Major Stock Purchase in Eli Lilly & Co! - TipRanks
Eli Lilly ramps up UK price of weight loss jab Mounjaro after Trump demands - The Guardian
Friday Five – Summer of the scythe, Padcev's perioperative promise, Lilly links with Superliminal for GPCR goals…and more - FirstWord Pharma
Deal Watch: Lilly Teams With GPCR-Focused Superluminal In Cardiometabolic Disease - insights.citeline.com
Texas AG Accuses Lilly Of Offering Providers Illegal Incentives - InkFreeNews.com
Superluminal joins a $1.3B deal with series A backer Lilly - BioWorld MedTech
Alvarez buys Eli Lilly shares worth $500k By Investing.com - Investing.com India
Cause Marketing: Eli Lilly Brings Free Mammograms and Health Education to WNBA All-Star Weekend - Event Marketer
Lilly says it will raise drug prices in Europe, responding to Trump threats - BioPharma Dive
Eli Lilly signs $1.3 billion deal with Superluminal to use AI to make obesity medicines - Fast Company
Eli Lilly and Company (LLY): “Wall Street Was Really Wrong,” Says Jim Cramer - Insider Monkey
Eli Lilly hikes weight-loss drug prices in Canada, Britain after pressure from Trump - The Globe and Mail
Eli Lilly Strikes $1.3B Superluminal Deal to Tackle Obesity and Cardiometabolic Diseases - USA Herald
Eli Lilly To Hike Mounjaro Prices By A Whopping 170% In UK: Retail Expects Stock To See Smooth Rally Till $720 - Stocktwits
Eli Lilly seeks more GPCR weight loss drugs in $1.3bn research deal - Pharmaceutical Technology
Eli Lilly Completes Phase 3 Study on Orforglipron for Obesity Treatment - TipRanks
Lilly invests in Boston biotech for $1.3B obesity drug deal - The Business Journals
Eli Lilly To Plug $1.3B Into Obesity-Focused Medicine Biz - Law360
Eli Lilly says it will raise drug prices in Europe to ‘make them lower’ in U.S. - statnews.com
Eli Lilly hikes price of diabetes drug Mounjaro in UK as Trump pressures pharma to align drug costs - CNBC
Lilly signs up to $1.3 billion deal with Superluminal to develop obesity medicines - Reuters
Eli Lilly to raise UK price of weight-loss drug Mounjaro by 170% - Business Standard
Lilly raises UK obesity shot price as Trump pressures pharma - Yahoo Finance
Pharmaceutical Industry Compliance Risks: Evaluating Eli Lilly's Legal Exposure and Its Implications for Big Pharma and Investors - AInvest
Why Is Eli Lilly Stock Climbing Thursday?Eli Lilly (NYSE:LLY) - Benzinga
Eli Lilly hikes UK price of blockbuster weight loss drug Mounjaro by up to 170% - Yahoo Life UK
Lilly to hike UK price of Mounjaro weight-loss drug by 170% - Reuters
Lilly hikes UK obesity shot price as Trump pressures drugmakers - The Detroit News
Texas sues Eli Lilly for allegedly bribing medical providers to prescribe its drugs - Investorsobserver
Lilly Hikes UK Obesity Shot Price as Trump Pressures Drugmakers - Bloomberg.com
Eli Lilly to hike UK price of Mounjaro weight-loss, diabetes medicines by 170% - TradingView
Eli Lilly raises UK price of weight loss drug Mounjaroreport - Investing.com
Eli Lilly raises UK price of obesity drug by up to 170% after Trump ‘freeloading’ gripe - Financial Times
Lilly signs up to $1.3 billion deal with Superluminal for obesity drugs - StreetInsider
Statement: America’s leading role in biopharmaceutical innovation - Eli Lilly and Company
Leap Therapeutics Slashes R&D Spending - The Motley Fool
UK prices for weight-loss jab jump by up to 170pc after Trump demands - The Telegraph
Eli Lilly's obesity drug "Munzaro" (component name Terzepatide) was released in Korea on the 14th. A.. - 매일경제
Top Executive Makes Major Investment in Eli Lilly & Co! - TipRanks
Texas Sues Eli Lilly: 'Big Pharma Compromised Medical Decision-Making' - Law.com
일라이 릴리 (LLY) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.21%
자본화:
|
볼륨(24시간):